Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

51.92 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 51.92
Bid (Size) 50.73 (1)
Ask (Size) 58.00 (1)
Prev. Close 51.92
Today's Range 51.92 - 51.92
52wk Range 50.27 - 75.74
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire

Performance

YTD
-20.67%
-20.67%
1 Month
-9.67%
-9.67%
3 Month
-15.58%
-15.58%
6 Month
-5.77%
-5.77%
1 Year
-31.00%
-31.00%

More News

Read More
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
Via Chartmill
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
From Incyte
Via Business Wire
NASDAQ:INCY, a growth stock which is not overvalued.
Via Chartmill
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
Via Chartmill
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
Via InvestorPlace
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
From Incyte Corporation
Via Business Wire
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
From Incyte
Via Business Wire
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Via InvestorPlace
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
From Incyte
Via Business Wire
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
Via Benzinga
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Via InvestorPlace
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
Via Chartmill
Exit Now! 3 Biotech Stocks to Sell in February 2024
Via InvestorPlace
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
From Incyte
Via Business Wire
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
Via Chartmill
Earnings Scheduled For February 13, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.